Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: An analysis of 215 patients registered in the international RIT-Network

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 8, 2014, Pages 1585-1592

  Hohloch, Karin ^a   Lankeit, H K ^a   Zinzani, P L ^b   Scholz, C W ^c   Lorsbach, M ^d   Windemuth Kieselbach, C ^d   Trumper L ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c HUMBOLDT UNIVERSITY   (Germany)

^d ALCEDIS GMBH   (Germany)

Author keywords

Diffuse large B cell lymphoma; First line therapy; Radioimmunotherapy; Registry data; Relapse; Therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; BLOOD CELL COUNT; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONSOLIDATION CHEMOTHERAPY; FEMALE; HISTOLOGY; HUMAN; INDUCTION CHEMOTHERAPY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; LYMPHOMA, B-CELL; MIDDLE AGED; REGISTER; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; REGISTRIES; TREATMENT OUTCOME;

EID: 84905563400     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2758-y     Document Type: Article

References (24)

1. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373-80. doi:10.1200/JCO.2009.26.2493.
2. Feugier P, Van HA, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23:4117-26. doi:10.1200/JCO.2005.09.131. (Pubitemid 46211317)
3. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634-41. doi:10.1182/blood-2003-06-2095. (Pubitemid 38970554)
4. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105-16. doi:10.1016/S1470- 2045(08)70002-0.
5. Gisselbrecht C, Glass B, Mounier N, Singh GD, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184-90. doi:10.1200/JCO.2010.28.1618.
6. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-63. (Pubitemid 34525730)
7. Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109:1804-10. doi:10.1002/cncr.22617. (Pubitemid 46668544)
8. Witzig TE, Fishkin P, Gordon LI, Gregory SA, Jacobs S, Macklis R, et al. Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Leuk Lymphoma. 2011;52:1188-99. doi:10.3109/10428194.2011.570396.
9. Zinzani PL, Gandolfi L, Stefoni V, Fanti S, Fina M, Pellegrini C, et al. Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. Clin Lymphoma Myeloma Leuk. 2010;10:258-61. doi:10.3816/CLML.2010.n.054.
10. Hamlin PA, Moskowitz CH, Wegner B, Noy A, Gerecitano J, Palomba ML, et al. Sequential RCHOP and yttrium-90 ibritumomab tiuxetan (RIT) is a highly effective regimen for high risk elderly patients with untreated DLBCL. Ann Oncol. 2008;19 Suppl 4:iv100. Abstract 054.
11. Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, Castellucci P, et al. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol. 2008;19:769-73. doi:10.1093/annonc/mdm560. (Pubitemid 351461050)
12. Zinzani PL, Rossi G, Franceschetti S, Botto B, Di RA, Cabras MG, et al. Phase II trial of short-course R-CHOP followed by 90Yibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. Clin Cancer Res. 2010;16:3998-4004. doi:10.1158/1078-0432.CCR-10-0162.
13. Yang DH, Kim WS, Kim SJ, Kim JS, Kwak JY, Chung JS, et al. Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. Leuk Lymphoma. 2012;53:807-11. doi:10.3109/10428194.2011.635857.
14. Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007;110:54-8. doi:10.1182/blood- 2007-01-068056. (Pubitemid 47026818)
15. Jaffe E, Harris N, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. WHO Classification of Tumours. Lyon: IARC; 2008.
16. Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013-22. doi:10.1016/S1470-2045(11)70235-2.
17. Borgerding A, Hasenkamp J, Glass B, Wulf G, Trumper L. Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Ann Hematol. 2010;89:283-9. doi:10.1007/s00277-009-0820-9.
18. Hagberg H, Gisselbrecht C. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol. 2006;17 Suppl 4:iv31-2. doi:10.1093/annonc/mdj996. (Pubitemid 43778973)
19. Martin A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica. 2008;93:1829-36. doi:10.3324/haematol.13440.
20. Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood. 2004;103:4429-31. doi:10.1182/blood-2003-11-3883. (Pubitemid 38745967)
21. El GT, Dupuis J, Belhadj K, Jais JP, Rahmouni A, Copie-Bergman C, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007;18:1363-8. doi:10.1093/annonc/mdm133. (Pubitemid 47305011)
22. Decaudin D, Mounier N, Tilly H, Ribrag V, Ghesquieres H, Bouabdallah K, et al. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. Clin Lymphoma Myeloma Leuk. 2011;11:212-8. doi:10.1016/j.clml.2011.03. 007.
23. Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012;118:4706-14. doi:10.1002/cncr.27418.
24. Illidge TM. Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date? J Clin Oncol. 2010;28:2944-6. doi:10.1200/JCO.2009.26.8748.